Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 10/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TOP2A | P11388 | 4/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066263 | 0.89 | NISCH (0.62) | NISCH | |
| SCHEMBL6745405 | 0.83 | NISCH (0.51) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL6745419 | 0.80 | NISCH (0.48) | NISCHGAATSHR | |
| SCHEMBL5307832 | 0.79 | TOP2A (0.61) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL5441899 | 0.79 | NISCH (0.59) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL13830922 | 0.79 | NISCH (0.58) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL14046102 | 0.79 | NISCH (0.58) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL6746742 | 0.79 | NISCH (0.80) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL4822597 | 0.79 | NISCH (0.80) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL11273702 | 0.79 | NISCH (0.58) | NISCHGAATSHRTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2933265-B1 | Pharmacological chaperones for treating obesity | AMICUS THERAPEUTICS INC (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-1885366-B1 | PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY | AMICUS THERAPEUTICS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9381194-B2 | Pharmacological chaperones for treating obesity | AMICUS THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2016056606-A1 | BENZOISOTHIAZOLOPYRIMIDINE DERIVATIVE AND SALT THEREOF,AND VIRAL INFECTION INHIBITOR AND DRUG | 国立大学法人京都大学 | 2016-04-14 | — | — | WO | disclosed |
| EP-2933265-A2 | Pharmacological chaperones for treating obesity | Amicus Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20090312345-A1 | PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY | AMICUS THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0799831-B1 | IR absorbing phthalocyanines | BASF AG (DE) | 2000-05-24 | — | — | EP | disclosed |
| US-5783694-A | IR-absorbing phthalocyanines | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| EP-0799831-A1 | IR absorbing phthalocyanines | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885GAA 2982/4885TSHR 47/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | NISCH 2500/4885GAA 2702/4885TSHR 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.